Previous close | 3.5320 |
Open | 3.5180 |
Bid | 3.4160 x 0 |
Ask | 3.6820 x 0 |
Day's range | 3.4680 - 3.5860 |
52-week range | 2.0750 - 7.2000 |
Volume | |
Avg. volume | 209 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Key Insights Given the large stake in the stock by institutions, Puma Biotechnology's stock price might be vulnerable...
Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.